Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (July 2026)
23 slides from Neurizon Therapeutics's investor presentation, Jul 29, 2026
Slide 1: Melbourne investor briefing presentation
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Melbourne investor briefing presentation 29 July 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing inn
Slide 2: Neurizon Investor Hub
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view vi
Slide 3: Shaping the future of neurodegenerative diseases
For personal use only Shaping the future of neurodegenerative diseases Neurizon Therapeutics Update - July 2026 ABN 35 094 006 023
Slide 4: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 5: Our Vision
For personal use only Our Vision To lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Slide 6: Investment Highlights
INVESTMENT HIGHLIGHTS 01 Why ALS (Amyotrophic 02 Why now For personal use only Lateral Sclerosis) Approaching a – ALS is a rapidly progressive, uniformly fatal neurodegenerative disease that destroys motor neurons, – Enrolled in registrational Phase 2/3 HEALEY ALS Trial under Regimen I — 250 partici
Slide 7: ALS: High Unmet Need with Significant Value Potential
ALS: High Unmet Need with Significant Value Potential Multiple large-value transactions and deals in recent years For personal use only Key ALS Value Reference Point: Shionogi – RADICAVA Other Recent ALS Deals US$2.5B Transaction (April 2026)1 Eli Lilly entered neurodegenerative disease collaboratio
Slide 8: Neurizon: From Scientific Origin to Clinical Execution
Neurizon: From Scientific Origin to Clinical Execution A unique, advanced opportunity in neurodegenerative diseases Well characterised drug Disease-modifying potential Strong foundation Late-stage clinical execution For personal use only 1 2 3 4 5 DISCOVERY & FOUNDATION TRANSLATION TO HUMAN DISEASE
Slide 9: NUZ-001 evaluated inside the largest independently sponsored ALS trial platform
NUZ-001 is being evaluated inside the largest independently sponsored ALS trial platform in the world NUZ-001 is independently adjudicated, randomised Ph2/3 asset with potential for accelerated approval For personal use only Independent sponsorship and Established site network validation WHAT HEALEY
Slide 10: Regimen I is designed to provide clinical signal
Regimen I is designed to provide clinical signal REGIMEN I AT A GLANCE WHY THESE DESIGN CHOICES MATTER For personal use only Design Double-blind, placebo-controlled adaptive Phase 2/3 under the HEALEY master protocol 36-week blinded period Participants 250 enrolled at close of recruitment (protocol
Slide 11: NUZ-001 Regulatory Strategy for ALS Market Access
NUZ-001 Regulatory Strategy for ALS Market Access Progressing a considered regulatory strategy across key jurisdictions, with a primary focus on the US For personal use only Orphan Drug Designation FDA Q2 Q3 Q3 H1 2024 2025 2026 2028 IND Clearance Type C Meeting NDA Submission Orphan Drug Design
Slide 12: Phase 1 Open Label Extension
Phase 1 Open Label Extension Generated clinical signals and established long-term tolerability to warrant clinical advancement For personal use only Highlights (Based on a study population of n=12 patients) Primary Outcome Slowed Functional Decline Respiratory Stabilisation • Long-term treatment wit
Slide 13: Preliminary Efficacy ALSFRS-R and SVC
Phase 1 Open Label Extension Preliminary Efficacy ALSFRS-R and SVC Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent For personal use only predicted (PP) when compared to matched controls from the
Slide 14: NUZ-001 shows improved survival vs matched controls
Phase 1 Open Label Extension NUZ-001 shows improved survival vs matched controls For personal use only NUZ-001 treatment resulted in statistically significantly longer survival of participants with ALS, (X2=11.35, p=0.00075), compared to matched controls1 from the PRO-ACT database2 Analysis suggests
Slide 15: Comparison of Approved ALS Treatments & NUZ-001
Comparison of Approved ALS Treatments & NUZ-001 Phase 1 study supports potential for significantly improved outcomes compared to existing treatments ALSFRS-R FVC/SVC Survival For personal use only (Improvement (Improvement (Improvement Compared to Placebo) Compared to Placebo) Compared to Placebo) A
Slide 16: NUZ-001 demonstrates encouraging biomarker trajectory
NUZ-001 demonstrates encouraging biomarker trajectory When compared with ALS natural history database NfL is a widely recognized, sensitive biomarker for ALS. The structural protein is released into the CSF (cerebrospinal fluid) or serum when For personal use only • nerves are damaged. It has been u
Slide 17: TDP-43 Aggregates are a Hallmark of ALS Pathology
TDP-43 Aggregates are a Hallmark of ALS Pathology Protein aggregates are cleared by multiple pathways including autophagy-lysosomal and ubiquitin-proteasome systems. Together these systems help to maintain proteostasis. For personal use only ALS Patient Population1 Spinal Cord Clearance of misfolded
Slide 18: NUZ-001 prevents TDP-43 aggregation and restores neuronal function
NUZ-001 prevents TDP-43 aggregation and restores neuronal function in human iPSC models For personal use only STMN2/DAPI TDP43/DAPI NUZ-001 prevents the formation of TDP-43 iPSC Motor aggregates and loss of Neurons Stathmin-21 expression 7 Day NUZ-001 vs MG132 treatment of TDP43 M337V motor neurons
Slide 19: NUZ-001: Platform Optionality for Proteinopathy-Driven Diseases
NUZ-001: Platform Optionality for Proteinopathy-Driven Diseases Strong mechanistic rationale for potential efficacy across a wide array of neurodegenerative diseases. Impaired proteostasis For personal use only contributes to the formation of intracellular inclusion bodies of misfolded proteins, a h
Slide 20: Capital Management Update
Capital Management Update Disciplined execution — three-part funding strategy progressing in line with expectations For personal use only Capital Allocation Funding Strategy Funding Strategy — — Three-Part Three-Part Framework Framework PLACEMENT COMPLETE ↓ Non-clinical spend reduced Pre-clinical, m
Slide 21: Expanding Relationship with Elanco
Expanding Relationship with Elanco Supports Neurizon’s advanced clinical positioning and commercial readiness For personal use only License Agreement Strategic Investment Supply Agreement The License Agreement was a foundational Elanco is now a top five shareholder in Neurizon has executed a long-te
Slide 22: Key Progress and Upcoming Milestones
Key Progress and Upcoming Milestones Upcoming Milestones Q3/Q4 Key Progress in Q2/Q3 For personal use only • CEO Appointment • Preclinical updates HEALEY Regimen I Ethics Approval for EMA Scientific Advice Data Strengthening Completed • HEALEY tablet supply secured through completion Liquid Formulat
Slide 23: Thank You
For personal use only Thank You Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com
Neurizon Therapeutics — Investor Presentation (July 2026) on 6ix